Targeted therapies in the treatment of advanced non-small-cell lung cancer: Update

Klinicka Onkologie

Volumn 22, Issue 4, 2009, Pages 131-138

  Mendoza, Luis ^a  

^a SYNEOS HEALTH   (United States)

Author keywords

EGFR; Non small cell lung carcinoma; Tyrosine kinase; VEGFR

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; TREATMENT RESPONSE; DRUG ANTAGONISM; LUNG TUMOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349307029     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Rapp E, Pater JL, Willan A et al. Chemotheraphy can prolong survival in patients with advanced non-smalll-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641
2. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase II trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734-1742.
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): 9-15.
4. Ohsaki Y, TANNO S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7: 603-607.
5. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact in prognosis. J Clin Oncol 2003; 21(20): 3798-3807. (Pubitemid 46606235)
6. Onn A, Choe DH, Herbst RS et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005; 237(1): 342-347. (Pubitemid 41346185)
7. Dacic S, Flanagan M, Cieply K et al. Significancer of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006; 125(6): 860-865. (Pubitemid 43801536)
8. Wislez M, Antoine M, Poulot V et al. IFCT0401-bio trial: predictive biological markers for disease control of patients with non-resectable, adenocarcinoma with bronchioloalveolar features treated with gefitinib. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7653.
9. Nakamura H, Kawasaki N, Taguchi M et al. Survival impact ofeppidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006; 61(2): 140-145. (Pubitemid 43235431)
10. Dassonville O, Bozec A, Fischell JL et al. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences. Crit Rev Oncol Hematol 2007; 62(1): 53-61. (Pubitemid 46330798)
11. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced no-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246. (Pubitemid 46621858)
12. Kris MG, Natale RB, Hebst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor TK, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158. (Pubitemid 37432975)
13. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II trial - INTACT 1. J Clin Oncol 2004; 22: 777-784. (Pubitemid 41103588)
14. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794. (Pubitemid 41103589)
15. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa Survical Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. (Pubitemid 41540110)
16. AstraZeneca. Gefitinib (IressaTM) marketing authorisation application withdrawn in EU. January 4, 2005. Available from: http://www.astrazeneca.com/ press-release/4442.aspx.
17. National Cancer Institute. Clinical Trial of Gefitinib for Advanced Lung Cancer Closes Early. April 18, 2005. Available from: http://www.nci.nih.gov/ newscenter/press-releases/gefitinibNSCLC.
18. Cufer T, Vrdoljak E, Gaafar R et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006; 17(4): 401-409. (Pubitemid 44309982)
19. Perez-Soler R, Chachoua A, Hammond LA et al. Determinats of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22(16): 3238-3247. (Pubitemid 41103678)
20. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12 (20 Pt 1): 6049-6055. (Pubitemid 44703768)
21. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotheraphy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25(7): 760-766. (Pubitemid 350002874)
22. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2007; 25(12): 1545-1552. (Pubitemid 46733081)
23. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phae III trial of erlotinib hydrodoride (OSI-774) combined with carboplatin and paclitaxel CT in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899. (Pubitemid 46300205)
24. Shepherd FA, Rodrigues Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell-lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
25. Janne PA, Gurubhagavatula S, Yeap BY et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (D1839, "Iressa") on an expanded access study. Lung Cancer 2004; 44(2): 221-230. (Pubitemid 38482055)
26. Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006; 1(9): 965-971.
27. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2): 133-144. (Pubitemid 41058345)
28. Lu JF, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80(2): 136-145. (Pubitemid 44160689)
29. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controled study in advanced non-small-cell lung cancer. Clin Oncol 2006; 24(1): 5034-5042.
30. Laack E, Schneider C, Gutjahr T et al. Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer. J Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7651.
31. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23(11): 8081-8092. (Pubitemid 46657411)
32. Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small-cell lung cancer. Clin Cancer Res 2005; 11(6): 2106-2110. (Pubitemid 40490166)
33. Murray S, Timotheadou E, Linardou H et al. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006; 52(2): 225-233.
34. Niho S, Kubota K, Goto K et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung canecr: a phase II study. J Clin Oncol 2006; 24(1): 1599-1603.
35. Ohtsuka K, Ohnishi H, Furuyashiki G et al. Clinico-pathological and biological significancer of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol 2006; 1(8): 787-795. (Pubitemid 47181383)
36. Wu YL, Zhong WZ, Li LY et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007; 2(5): 430-439.
37. Kashii T, Okamoto I, Urata Y et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer patients: results of West Japan Thoracic Oncology Group Trial (WJTOG0403). 31st ESMO Congress 2006. Abstract 717.
38. Porta R, Terrasa J, Rolfo C et al. Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer patients based on the presence of mutations in the TK domain of the epidermal growth factor receptor. 31st ESMO Congress 2006. Abstract 719.
39. Massuti B, Reguart N, Vivanco GL et al. First-line erlotinib in stage IV non-small-cell lung cancer patients with mutations in the TK domain of the epidermal growth factor receptor. 31st ESMO Congress 2006. Abstract 720.
40. Cappuzzo F, Hirsh FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655. (Pubitemid 40812628)
41. Lynch TJ, Lilenbaum R, Bonomi P et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 634. Abstract 7084.
42. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19(2): 362-369. (Pubitemid 351201721)
43. Pirker R, Szczesna A, Von Pawel J et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008; 26. Abstract 3.
44. Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 634. Abstract 7083.
45. Cappuzzo F, Varella-Garcia M, Shigematsu H et al. Increased HER2 gene copy number associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23(22): 5007-5018. (Pubitemid 46224007)
46. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12 (14 Pt 2): 4377-4383.
47. Langer CJ, Stephenson P, Thor A et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004; 22(7): 1180-1187. (Pubitemid 41079829)
48. Herbst RS, Davies AM, Natale RB et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13(20): 6175-6181.
49. Herbst RS, Hidalgo M, Pierson AS et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002; 29 (Suppl 4): 66-77. (Pubitemid 34226521)
50. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191. (Pubitemid 41095154)
51. Sandler AB, Gray R, Perry M et al. Paclitaxel-Carboplatin Alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
52. Manegold C, Von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract LBA 7514.
53. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26(11): 1871-1878.
54. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655. (Pubitemid 34898591)
55. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a VEGF receptor TK inhibitor, in human cancer cells with acquired resistance o antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-793. (Pubitemid 38174017)
56. Taguchi F, Koh Y, Koizumi F et al. Anticancer effects of ZD6474, a VEGF receptor TK inhibitor, in gefitinib (Iressa)-sensitive and resistant xenograft models. Cancer Sci 2004; 95: 984-989. (Pubitemid 40089591)
57. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic nd therapeutic implications. J Clin Oncol 2005; 23(14): 3243-3256. (Pubitemid 46211349)
58. Johnson BE, Ma P, West H et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc Am Soc Clin Oncol 2005; 23: 16. Abstract 7102.
59. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25(27): 4270-4277. (Pubitemid 47548567)
60. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 7000.
61. Wilhelm SM, Carter C, Tang LY et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and target the RAF/MEK/ERK pathway and receptor TKs involved in tumor progression and angiogenesis. Cancer Res 2005; 64: 7099-7109. (Pubitemid 39331023)
62. Adams J, Huang P, Patrick D. A strategy for the design of multiple inhibitors for kinase-medited signalling in agiogenesis. Curr Opin Chem Biol 2002; 6: 486-492.
63. Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59(2): 183-195. (Pubitemid 44885148)
64. Liu B, Barett T, Choyke P et al. A phase II study BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 17119.
65. Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2006; 24: 18. Abstract 7002.
66. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 TK inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605. (Pubitemid 36857948)
67. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(4): 650-656. (Pubitemid 351264362)
68. Brahmer JR, Govindan S, Novello R et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. Proc Am Soc Clin Oncol 2007; 25: 18. Abstract 7542.